Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDZ9LT)

Drug Name
Ethosuximide Drug Info
Synonyms
Aethosuccimidum; Aethosuximide; Asamid; Atysmal; Capitus; Emeside; Ethosuccimid; Ethosuccimide; Ethosuccinimide; Ethosuxide; Ethosuximidum; Ethylmethylsuccimide; Ethymal; Etomal; Etosuccimide; Etosuximid; Etosuximida; Etosuximide; Mesentol; Pemal; Pemalin; Pentinimid; Peptinimid; Petinimid; Petnidan; Piknolepsin; Pyknolepsinum; Ronton; Simatin; Succimal; Succimitin; Suksilep; Suxilep; Suximal; Suxin; Suxinutin; Thetamid; Thilopemal; Zaraondan; Zarodan; Zarondan; Zarontin; Zartalin; Aethosuximide [German]; Desitin Brand of Ethosuximide; Epileo Petit MAL; Etosuccimide [DCIT]; Etosuximida Faes; Faes Brand of Ethosuximide; Fortbenton Brand of Ethosuximide; Jenapharm Brand of Ethosuximide; Katwijk Brand of Ethosuximide; LAB Brand of Ethosuximide; Parke Davis Brand of Ethosuximide; Pfizer Brand of Ethosuximide; United Drug Brand of Ethosuximide; Warner Lambert Brand of Ethosuximide; Wernigerode Brand of Ethosuximide; Cl 366; E 7138; E0746; H 940; PM 671; CN-10395; Ethosuximidum [INN-Latin]; Etosuximida [INN-Spanish]; Faes, Etosuximida; H-490; N-Ethyl methylsuccinimide; PM-671; Simatin(E); Warner-Lambert Brand of Ethosuximide; Zarondan-Saft; Zarontin (TN); C.I. 366; CN-10,395; Piknole.psi.n; Pyknole.psi.num; Alpha-Ethyl-alpha-methylsuccinimide; Alpha-Methyl-alpha-ethylsuccinimide; Ethosuximide (JP15/USP/INN); Ethosuximide [USAN:INN:BAN:JAN]; Gamma-Methyl-gamma-ethylsuccinimide; Gamma-Methyl-gamma-ethyl-succinimide; Gamma-ethyl-gamma-methyl-succinimide; (+-)-2-Ethyl-2-methylsuccinimide; 2-Ethyl-2-methylsuccinimide; 2-Methyl-2-ethylsuccinimide; 3-Ethyl-3-methyl-2, 5-pyrrolidinedion; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; 3-Ethyl-3-methylpyrrolidine-2,5-dione; 3-Ethyl-3-methylpyrroline-2,5-dione; 3-Ethyl-3-methylsuccinimide; 3-Methyl-3-ethylpyrrolidine-2,5-dione; 3-Methyl-3-ethylsuccinimide
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1]
Therapeutic Class
Analgesics
Cross-matching ID
PubChem CID
3291
ChEBI ID
CHEBI:4887
CAS Number
CAS 77-67-8
TTD Drug ID
DMDZ9LT
INTEDE Drug ID
DR0659
ACDINA Drug ID
D00254

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [6]
Trimethadione DM0Q8MZ Absence epilepsy Approved [7]
Paramethadione DMR5ZUP Absence epilepsy Approved [7]
Methsuximide DM6L5VO Absence epilepsy Approved [8]
Penfluridol DMG1DTE Schizophrenia 6A20 Approved [9]
PD-200390 DMPW28M Insomnia 7A00-7A0Z Phase 2 [10]
NGD 94-1 DMM1Y8F Schizophrenia 6A20 Phase 1 [9]
ML218 DM3D21X Discovery agent N.A. Investigative [11]
KYS-05001 DM3MID9 Discovery agent N.A. Investigative [12]
KYS-05077 DMHW40F Discovery agent N.A. Investigative [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [14]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [15]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [16]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [17]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [18]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [19]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [20]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [21]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [15]
Verapamil DMA7PEW Angina pectoris BA40 Approved [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [23]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [24]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [25]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [26]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [27]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [28]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [29]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [30]
Verapamil DMA7PEW Angina pectoris BA40 Approved [31]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2E1 (CYP2E1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Folic Acid DMEMBJC Colorectal carcinoma Approved [32]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [33]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [34]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [35]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [36]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [37]
Verapamil DMA7PEW Angina pectoris BA40 Approved [38]
Estrone DM5T6US Acne vulgaris ED80 Approved [39]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [40]
Ethanol DMDRQZU Chronic pain MG30 Approved [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [42]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [26]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [26]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [26]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [38]
Verapamil DMA7PEW Angina pectoris BA40 Approved [43]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [26]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [26]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [26]
Metronidazole DMTIVEN Abscess Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A43 (CYP3A43)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zalcitabine DMH7MUV Human immunodeficiency virus infection 1C62 Approved [45]
Oxazepam DMXNZM4 Alcohol withdrawal delirium Approved [46]
Praziquantel DMOU1PK Flatworm infection 1F70-1F86 Approved [47]
Testosterone cypionate DMC1TEV N. A. N. A. Approved [48]
Drug(s) Affected By Aromatase (CYP19A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Letrozole DMH07Y3 Estrogen-receptor positive breast cancer Approved [49]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [50]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [51]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [52]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [51]
Methotrexate DM2TEOL Anterior urethra cancer Approved [53]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [54]
Bifonazole DM3KN7V Fungal infection 1F29-1F2F Approved [55]
Quercetin DM3NC4M Obesity 5B81 Approved [56]
Fluoxetine DM3PD2C Bipolar depression Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By HLA class II histocompatibility antigen, DP alpha 1 chain (HLA-DPA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [57]
Fluoxetine DM3PD2C Bipolar depression Approved [5]
Cinoxacin DM4EWNS Urinary tract infection GC08 Approved [5]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [58]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [59]
Testosterone DM7HUNW Hot flushes GA30 Approved [60]
Valdecoxib DMAY7H4 Osteoarthritis FA00-FA05 Approved [5]
Testosterone enanthate DMB6871 N. A. N. A. Approved [61]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [62]
Cephalexin DMD5JU8 Acute otitis media AB00 Approved [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By HLA class II histocompatibility antigen, DM beta chain (HLA-DMB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Topiramate DM82Z30 Alcohol dependence 6C40.2 Approved [5]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [63]
Valdecoxib DMAY7H4 Osteoarthritis FA00-FA05 Approved [5]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [64]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [65]
Vancomycin DM3JFIH Bacteremia 1A73 Approved [5]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [66]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [67]
Bortezomib DMNO38U Leukemia Approved [68]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) TT729IR CAC1G_HUMAN Blocker [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [3]
Cytochrome P450 2E1 (CYP2E1) Main DME DEVDYN7 CP2E1_HUMAN Substrate [3]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [3]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [3]
Cytochrome P450 3A43 (CYP3A43) DEO1IE3 CP343_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Gene/Protein Processing [4]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB) OT17HGXJ DMB_HUMAN Gene/Protein Processing [5]
HLA class II histocompatibility antigen, DP alpha 1 chain (HLA-DPA1) OT7OG7Y2 DPA1_HUMAN Gene/Protein Processing [5]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7182).
2 Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
3 Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
4 Inhibition of human aromatase complex (CYP19) by antiepileptic drugs. Toxicol In Vitro. 2008 Feb;22(1):146-53.
5 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
6 Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
7 Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
8 Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
9 Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
10 Pfizer. Product Development Pipeline. March 31 2009.
11 The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
12 Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.
13 Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
24 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
25 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
26 Drug Interactions Flockhart Table
27 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
28 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
29 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
30 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
31 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
32 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
33 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
34 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
35 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
36 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
37 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
38 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
39 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
40 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
41 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
42 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
43 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
44 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
45 Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
46 Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
47 Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
48 cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001 Feb;59(2):386-92.
49 Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
50 Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling. Reprod Toxicol. 2020 Apr;93:75-82. doi: 10.1016/j.reprotox.2020.01.003. Epub 2020 Jan 14.
51 Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
52 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
53 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
54 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
55 Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
56 Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol. 1999 Dec 31;71(5-6):223-30.
57 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
58 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
59 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
60 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
61 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
62 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
63 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
64 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
65 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
66 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
67 Chromosomal radiosensitivity in two cell lineages derived from clinically radiosensitive cancer patients. Clin Cancer Res. 2005 Sep 1;11(17):6352-8. doi: 10.1158/1078-0432.CCR-04-1931.
68 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.